Sumatriptan Succinate Injection

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2D2-23-R-0006

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

-

SourceSAM
Documents3
The Defense Logistics Agency (DLA) Troop Support has issued a solicitation (SPE2D2-23-R-0006) for the procurement of Sumatriptan Succinate Injection under a national contracts framework. This opportunity is classified under NAICS code 325412, which pertains to Pharmaceutical Preparation Manufacturing, and is further identified by Product Service Code 6505, indicating a focus on drugs and biologicals. The primary objective of this procurement is to establish a reliable supply chain for Sumatriptan Succinate Injection, a critical pharmaceutical product used in the treatment of migraine headaches. Through this solicitation, DLA Troop Support seeks to secure national contracts that will ensure the consistent availability and timely delivery of this medication to meet the needs of its federal stakeholders, including military and other government healthcare facilities. Contractors responding to this solicitation are expected to demonstrate their capability to manufacture and supply Sumatriptan Succinate Injection in accordance with all applicable federal regulations and quality standards. Key requirements likely include adherence to current Good Manufacturing Practices (cGMP), FDA approval for the product, and the ability to meet specified delivery schedules and quantities as outlined in the solicitation attachments. The contracting activity is managed by DLA Troop Support, a federal office responsible for providing medical and pharmaceutical supplies to the Department of Defense and other federal agencies. Interested parties may direct inquiries to the primary contact, Ryan Ferry ([email protected], 215-737-3182), or the secondary contact, Jason Wray ([email protected], 215-737-0614), for further information regarding the solicitation requirements and submission process. This solicitation is currently active, with the notice posted on July 6, 2023. Contractors are encouraged to review the full solicitation and its attachments, available via the official SAM.gov opportunity listing (https://sam.gov/opp/03aea7804dae447f8f2873bc3747ded8/view), to ensure a comprehensive understanding of the scope, deliverables, and compliance expectations. No specific set-aside requirements or special considerations are indicated in the provided information. Overall, this procurement represents a significant opportunity for qualified pharmaceutical manufacturers to partner with DLA Troop Support in supporting the medical readiness and healthcare needs of federal agencies through the supply of Sumatriptan Succinate Injection.